DelveInsight’s “Optic Neuritis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Optic Neuritis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Optic Neuritis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Optic Neuritis Overview
Optic neuritis is an inflammatory condition affecting the optic nerve, which transmits visual information from the eye to the brain. This inflammation leads to symptoms such as vision loss, pain, and visual disturbances. It often presents as a sudden decrease in vision, typically in one eye, accompanied by pain that worsens with eye movement.
Causes and Risk Factors
Optic neuritis can be caused by various factors, including:
-
Autoimmune Disorders: It is commonly associated with multiple sclerosis (MS), where the body's immune system attacks the myelin sheath of the optic nerve.
-
Infections: Viral or bacterial infections can lead to inflammation of the optic nerve.
-
Other Inflammatory Conditions: Conditions such as neuromyelitis optica (NMO) and systemic lupus erythematosus (SLE) may also cause optic neuritis.
-
Medications and Toxins: Certain drugs and toxins might trigger optic nerve inflammation.
Symptoms
Common symptoms of optic neuritis include:
-
Vision Loss: Gradual or sudden loss of vision in one eye.
-
Pain: Eye pain, especially during eye movement.
-
Color Vision Changes: Difficulty distinguishing colors.
-
Visual Disturbances: Blurred or dim vision, or seeing flashes of light.
Diagnosis
Diagnosis of optic neuritis involves a combination of:
Clinical Examination: Assessment of visual acuity, eye movements, and pupillary responses.
Imaging: Magnetic resonance imaging (MRI) of the brain and optic nerves to identify inflammation and rule out other conditions.
Lumbar Puncture: Analysis of cerebrospinal fluid to detect signs of inflammation or demyelination.
Visual Evoked Potentials (VEP): Tests that measure the electrical activity in the brain in response to visual stimuli.
Treatment
Treatment for optic neuritis may include:
-
Steroids: High-dose corticosteroids are commonly used to reduce inflammation and speed up recovery.
-
Disease-Modifying Therapies: For those with underlying conditions like MS, medications to manage the disease can help prevent future episodes.
-
Supportive Care: Pain management and visual rehabilitation may be necessary.
Prognosis
The prognosis for optic neuritis varies. Many patients experience significant improvement in vision within months, though some may have residual visual deficits. Early treatment and management of underlying conditions can enhance recovery and reduce the risk of recurrence.
Current Research and Market Trends
The optic neuritis therapeutics market is evolving with increased research and development efforts focusing on novel treatments. Emerging therapies and advancements in understanding the condition are expected to drive growth in this market, with key players like Accure Therapeutics, Mitochon Pharmaceuticals, and Noveome Biotherapeutics leading the way.
Optic Neuritis Market Key Facts
-
According to DelveInsight, the Optic Neuritis market in 7MM is expected to witness a major change in the study period 2019-2032.
-
Leading Optic Neuritis companies working in the market are Aerie Pharmaceuticals, Abbvie, Bausch Health Companies Inc., Merck, Pfizer, Teva Pharmaceutical, EyePoint Pharmaceuticals, Amorphex Therapeutics Holdings, Kubota Vision, Alcon Vision LLC, Ellex Medical, Lumenis Be Ltd, Acorn Biomedical, Astellas Pharma, Glenmark Pharmaceuticals, Bayer, Novartis AG, and others.
The report's outlook on the optic neuritis market provides a comprehensive understanding of historical, current, and projected trends. It examines the impact of existing optic neuritis therapies, identifies unmet needs, and explores market drivers, barriers, and the demand for advanced technologies.
This section offers an in-depth analysis of market trends for each marketed drug and late-stage pipeline therapy. It evaluates their influence based on factors such as annual therapy costs, inclusion and exclusion criteria, mechanisms of action, compliance rates, market demand, patient demographics, expected launch dates, competition with other treatments, brand value, and insights from key opinion leaders. Market data is presented with relevant tables and graphs to provide a clear and immediate overview.
According to DelveInsight, the optic neuritis market across the 7MM is anticipated to undergo significant changes during the study period from 2019 to 2032.
Optic Neuritis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
Optic Neuritis Therapeutics Analysis
Advances in technology and a deeper understanding of optic neuritis, particularly its connection with Multiple Sclerosis, have created promising opportunities for new research and the development of innovative treatment approaches. Major pharmaceutical and biotech companies, including Iogen, Mitochon Pharmaceuticals, and Noveome Biotherapeutics, are actively engaged in enhancing therapeutic options for optic neuritis. The introduction of new therapies from the pipeline is anticipated to significantly alter treatment practices for optic neuritis in the near future.
Leading Companies in the Optic Neuritis Therapeutics Market Include:
-
Accure Therapeutics
-
Mitochon Pharmaceuticals
-
Noveome
-
Questcor
-
Biogen
Optic Neuritis Therapies Covered in the Report Include:
-
ACT-01: Accure Therapeutics
-
MP-101: Mitochon Pharmaceuticals
-
ST266: Noveome
-
H.P. Acthar Gel (repository corticotropin) Injection: Questcor
-
Opicinumab: Biogen
Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/optic-neuritis-market
Table of Contents:
1. Key Insights
2. Executive Summary
3. Optic Neuritis Competitive Intelligence Analysis
4. Optic Neuritis Market Overview at a Glance
5. Optic Neuritis Disease Background and Overview
6. Optic Neuritis Patient Journey
7. Optic Neuritis Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Optic Neuritis Treatment Algorithm, Current Treatment, and Medical Practices
9. Optic Neuritis Unmet Needs
10. Key Endpoints of Optic Neuritis Treatment
11. Optic Neuritis Marketed Products
12. Optic Neuritis Emerging Drugs and Latest Therapeutic Advances
13. Optic Neuritis Seven Major Market Analysis
14. Attribute Analysis
15. Optic Neuritis Market Outlook (In US, EU5, and Japan)
16. Optic Neuritis Access and Reimbursement Overview
17. KOL Views on the Optic Neuritis Market
18. Optic Neuritis Market Drivers
19. Optic Neuritis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Download the Sample PDF to Learn More About the Key Offerings of the Report @ https://www.delveinsight.com/sample-request/optic-neuritis-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
